(Q24201767)

30 June 2019

meta-analysis

0 references

title

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia (English)

1 reference

30 June 2019

author

Leonard Leibovici

6

0 references

Mical Paul

1

0 references

Karla Soares-Weiser

5

0 references

Yaakov Dickstein

2

object named as

Yaakov Dickstein

1 reference

30 June 2019

Simona Grozinsky-Glasberg

4

object named as

Simona Grozinsky-Glasberg

1 reference

30 June 2019

Agata Schlesinger

3

object named as

Agata Schlesinger

1 reference

30 June 2019

publication date

29 June 2013

1 reference

30 June 2019

Cochrane Database of Systematic Reviews

published in

1 reference

30 June 2019

issue

6

1 reference

30 June 2019

page(s)

CD003038

1 reference

30 June 2019

Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Treatment of neutropenic infection: a randomized trial comparing latamoxef (moxalactam) with cephradine plus tobramycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Comparison of imipenem versus cefuroxime plus tobramycin as empirical therapy for febrile granulocytopenic patients and efficacy of vancomycin and aztreonam in case of failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Ceftazidime as a single agent in the management of children with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Imipenem/cilastatin versus piperacillin plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with haematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

A prospective randomized study comparing the efficacy of Timentin alone or in combination with amikacin in the treatment of febrile neutropenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Randomized Comparison of Ceftriaxone versus Cefriaxone plus Amikacin for the Empirical Treatment of Infections in Patients with Altered Host Defense: Microbiological and Clinical Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Imipenem-antibiotic monotherapy in juvenile cancer patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Comparative study of ceftriaxone monotherapy versus a combination regimen of cefuroxime plus gentamicin for treatment of serious bacterial infections: the efficacy, safety and effect on fecal flora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Ceftazidime compared to tobramycin and ticarcillin in immunocompromised haematological patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Infections in cancer patients.Results with gentamicin sulfate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Single versus combination intravenous antibiotic therapy for people with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Can

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Treatment of septicaemia in immunocompromised patients with ceftazidime or with tobramycin and cefuroxime, with special reference to renal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038.PUB2

Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors

21 January 2018

1 reference

12 December 2020

Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.

1 reference

12 December 2020

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy

1 reference

12 December 2020

Fever and neutropenia in children with cancer: a new therapeutic proposal

1 reference

12 December 2020

Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study

1 reference

12 December 2020

A Comparison of Imipenem to Ceftazidime With or Without Amikacin as Empiric Therapy in Febrile Neutropenic Patients

1 reference

12 December 2020

A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer

1 reference

12 December 2020

Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy

1 reference

12 December 2020

Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.

1 reference

12 December 2020

From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever

1 reference

12 December 2020

From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel

1 reference

12 December 2020

[Assessment of the efficacy of treating infections in hematopoietic proliferative diseases: Monotherapy with ceftazidime and tobramycin combined with amoxycillin/ampicillin]

1 reference

12 December 2020

Antibiotic therapy for the febrile granulocytopenic cancer patient: combination therapy vs. monotherapy.

1 reference

12 December 2020

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

1 reference

12 December 2020

First-line treatment of febrile episodes in leukemia in adults. Randomized, multicenter study of ceftazidime in single antibiotic therapy versus a cefotaxime-amikacin combination

1 reference

12 December 2020

Randomized prospective study of ceftazidime versus a cefotaxime-tobramycin combination in acute leukemia in therapeutic aplasia

1 reference

12 December 2020

Antibiotic therapy protocol using ceftazidime 3g/day alone or in combination with vancomycin or amikacin. In febrile episodes in neutropenic patients

1 reference

12 December 2020

Development of resistance during antibiotic therapy

1 reference

12 December 2020

Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study

1 reference

12 December 2020

Cefmenoxime or piperacillin plus amikacin. A prospective randomized comparison of empiric antibiotic therapy of febrile granulocytopenic cancer patients

1 reference

12 December 2020

Empiric antibiotic therapy for granulocytopenic cancer patients

1 reference

12 December 2020

Latamoxef versus carbenicillin plus gentamicin or carbenicillin plus mecillinam in leukopenic, febrile patients with solid tumors

1 reference

12 December 2020

Gram-negative bacterial infections: a look at the past, a view of the present, and a glance at the future

1 reference

12 December 2020

Management of infections caused by gram-negative bacilli: the role of antimicrobial combinations

1 reference

12 December 2020

Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients

1 reference

12 December 2020

Comparative efficacy and toxicity of moxalactam and the combination of nafcillin and tobramycin in febrile granulocytopenic patients

1 reference

12 December 2020

Empiric therapy of infections in hematologic malignancies: a prospective, randomized trial

1 reference

12 December 2020

Synergistic combinations of antibiotics in gram-negative bacillary infections.

1 reference

12 December 2020

Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients

1 reference

12 December 2020

Randomised study comparing imipenem/cilastatin to ceftriaxone plus gentamicin in cancer chemotherapy-induced neutropenic fever

1 reference

12 December 2020

A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients.

1 reference

12 December 2020

Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial

1 reference

12 December 2020

Initial empiric therapy for fever in neutropenia.

1 reference

12 December 2020

Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients

1 reference

12 December 2020

Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients

1 reference

12 December 2020

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Re

1 reference

12 December 2020

Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders

1 reference

12 December 2020

Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.

1 reference

12 December 2020

Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials

1 reference

12 December 2020

Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients

1 reference

12 December 2020

Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study

1 reference

12 December 2020

Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients

1 reference

12 December 2020

Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients

1 reference

12 December 2020

Synergism between amikacin and cefazolin against Klebsiella: in vitro studies and effect on the bactericidal activity of serum

1 reference

12 December 2020

10.1002/14651858.CD003038.PUB2

Identifiers

DOI

1 reference

30 June 2019

release_kdqso4zcdfhmtbryllx4zznfry

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kdqso4zcdfhmtbryllx4zznfry

24 November 2022

mapped directly with Wikidata item

PMCID

6457814

1 reference

30 June 2019

PubMed ID

23813455

1 reference

30 June 2019